Abstract
BackgroundThe inflamed immune phenotype (IIP), defined by enrichment of tumor-infiltrating lymphocytes (TILs) within intratumoral areas, is a promising tumor-agnostic biomarker of response to immune checkpoint inhibitor (ICI) therapy. However, it...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have